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SUPERIOR COURT
CIVIL ACTION
Docket No.

STATE OF MAINE
KENNEBEC, SS.

STATE O F MAINE

Plaintiff,

v.
ASTRAZENECA PHARMACEUTICALS L P
and
ASTRAZENECA LP
Defendants

1.

)
)
)
)
)
)
)
)
)
)
)

COMPLAINT
(Injunctive Relief Requested)

)
)
)

Plaintiff the State of Maine, by and through its Attorney General William J,

Schneider, brings this action complaining of Defendant ASTRAZENECA
PHARMACEUTICALS LP and ASTRAZENECA TP, Delaware corporations, for violating the
Maine Un&ir Trade Practices Act and the Uniform Deceptive Trade Practices Act as follows:
JURISDICTION AND VENUE
2.

This Court has jurisdiction over the subject matter and Defendants o f this action

pursuant to 5 M.R.S. § 209 because the Defendants have transacted business within the state of
Maine at all times relevant to this complaint
3.

In accordance with 5 M,R.S. § 209, venue is proper in this court.
PARTIES

4.

Plaintiff, the State o f Maine, is represented by the Attorney General who brings this

action in the public interest pursuant to 5 M.R.S. § 209.

10.

Seroquel received approval from the U.S. Food and Drug Administration (hereinafter

“FDA”), for the treatment of manifestations o f psychotic disorders, including schizophrenia, on
September 26,1997.
11.

FDA narrowed Seroquel’s label to “indicated for the treatment o f schizophrenia” on

March 27,2001.
ASTRAZENECA’S M ARKETING OF SEROQUEL
12.

Maine permits physicians to prescribe FDA-approved drugs for conditions or diseases

for which FDA approval has not been obtained when, through the exercise of independent
professional judgment, the physician determines the drug in question is an appropriate treatment
for an individual patient. This practice is referred to as "off-label prescribing.”
13.

However, pharmaceutical manufacturers may not promote or market their products

for any use not specifically approved by the FDA. This practice is known as “off-label
marketing.”
14.

Before late 2009, Seroquel was approved by the FDA only for the treatment of certain

specific conditions in adults, primarily conditions related to Schizophrenia and Bipolar Mania.
15.

Despite having narrow FDA approval for adults only, AstraZeneca promoted and

marketed the drug for the treatment o f a variety o f conditions and to a variety o f patient
populations not included among the FDA-approved indications, including for the treatment of
anxiety, depression, sleep disorders, and post traumatic stress disorder, and to child and geriatric
populations.
16.

Through this off-label marketing, AstraZeneca aimed to enhance Seroquel7s market

penetration across a wide range of diagnoses and patient populations.
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17.

AstraZeneca promoted Seroquel’s use in children and adolescents long before

establishing that it was safe or effective for any use in this population.
18.

AstraZeneca promoted Seroquel to treat dementia and Alzheimer’s Disease in the

elderly even though Seroquel has never been approved for the treatment of these conditions and
AstraZeneca has not established that Seroquel is safe and effective for these uses.
19.

AstraZeneca also masked, withheld, or failed to disclose negative information

contained in scientific studies concerning the safety and efficacy o f Seroquel.
20.

AstraZeneca foiled to adequately disclose the risks associated with Seroquel’s use by,

among other things, minimizing the risk o f hyperglycemia and diabetes mellitus and failing to
communicate important information regarding neuroleptic malignant syndrome, tardive
dyskinesia, and the risk of bolded cataracts.
APPLICABLE STATUTES
21.

Section 207 o f the Maine Unfair Trade Practices Act, states in relevant part as

follows:
Unfair methods of competition and unfair or deceptive acts or practices in the conduct
o f any trade or commerce are declared unlawful.
5M.R.S. §207.

22.

Section 1212 of the Uniform Deceptive Trade Practices Act, states in relevant part

as follows:
1. Lists. A person engages in a deceptive trade practice when, in the course o f his
business, vocation or occupation, he:
(E)
represents that goods or services have sponsorship, ingredients, uses,
benefits or quantities that they do not have ,..;
(L)
engages in any other conduct which similarly creates a likelihood of
confusion or of misunderstanding.
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2. Complaint. In order to prevail in an action under this chapter, a complainant need
not prove competition between the parties or actual confusion or misunderstanding.

10M.R.S.S 1212.
23.

Section 1211(5) of the Uniform Deceptive Trade Practices Act, states in relevant

part as follows: “’person' means an individual, corporation...or any other legal or commercial
entity.” 10M.R.S. § 1211(5).

VIOLATIONS OF LAW
COUNT I - M AINE UNFAIR TRADE PRACTICES ACT
24.

The Plaintiff realleges and incorporates each and every allegation contained in the

preceding paragraphs 1 through 23.
25.

AstraZeneca, in the course of marketing, promoting, selling, and distributing the

prescription drug Seroquel has engaged in a course of trade or commerce which constitutes
unfair, deceptive, or misleading practices, and is therefore unlawful under Section 207 o f the
Maine Unfair Trade Practices Act by promoting Seroquel for uses that have not been shown to
be safe or effective and by failing to adequately disclose the risks associated with SeroqueTs use.

COUNT II - UNIFORM DECEPTIVE TRADE PRACTICES ACT
26.

The Plaintiff realleges and incorporates each and every allegation contained in the

preceding paragraphs 1 through 25,
27.

AstraZeneca, in the course of marketing, promoting, selling, and distributing the

prescription drug Seroquel has engaged in a course of trade or commerce which constitutes
unfair, deceptive, or misleading practices, and is therefore unlawful under Section 1212 o f the
Uniform Deceptive Trade Practices Act by promoting Seroquel for uses that have not been
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shown to be safe or effective and by failing to adequately disclose the risks associated with
Seroquel’s use.
REM EDIES
1. Section 209 of the Maine Unfair Trade Practices Act states in relevant part as
follows:
Whenever the Attorney General has reason to believe that any person is using or is
about to use any method, act or practice declared by section 207 to be unlawful, and
that proceedings would be in the public interest, he may bring an action in the name
of the State against such person to restrain by temporary or permanent injunction the
use of such method, act or practice__
Each intentional violation of section 207 in which the Attorney General establishes
that the conduct giving rise to the violation is either unfair or deceptive is a violation
for which a civil penalty of not more than $10,000 shall be adjudged. Ih e Attorney
General may seek to recover civil penalties for violations o f section 207 which are
intentional and are unfair or deceptive.
In any action under this section where a permanent injunction is issued, the court may
order the person against whom the permanent injunction has been issued to pay to the
State the costs of the investigation o f that person by the Attorney General and the
costs of the suit, which funds shall accrue to the General Fund.
5 M.R.S. § 209.
2.

Section 1213 of the Uniform Deceptive Trade Practices Act, 5 M.R.S. § 1213,

provides:
A person likely to be damaged by a deceptive trade practice o f another may be
granted injunctive relief upon terms that the court considers reasonable. Proof of
monetary damage, lbss of profits or intent to deceive is not requiredThe relief provided in this section is in addition to remedies otherwise available
against the same conduct under the common law or other statutes of this State.
PRAYER F O R R ELIEF
WHEREFORE, the Plaintiff respectfully requests that this honorable Court enter an
order:
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A.

Issuing a permanent injunction prohibiting Defendants, their agents, employees,

and all other persons and entities, corporate or otherwise, in active concert or participation with
any of them, from engaging in unfair, deceptive or misleading conduct;
B.

Ordering Defendants to pay civil penalties of up to $10,000 for each intentional

violation of the Maine Unfair Trade Practices Act, as provided by 5 M.R.S. § 209;
C.

Ordering Defendants to pay all costs for the prosecution and investigation o f this

action, as provided by 5 M.R.S. § 209;
D.

Granting such other and further relief as the Court deems equitable and proper.

Dated at Augusta, Maine this 10th day of March, 2011.

Respectfully submitted,
State of Maine, by
its Attorney General
WILLIAM J. SCHNEIDER

Maine Bar No. 7095
Office o f the Attorney General
6 State House Station
Augusta, Maine 04333-0006
207/626-B800
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